Clearmind Medicine (CMND) announces that it initiated its Phase I/IIa clinical trial investigating the safety, tolerability and full pharmacokinetic profile of its innovative treatment, CMND-100, in Alcohol Use Disorder patients. This study is the first clinical application of the Company’s proprietary CMND-100 platform and marks a significant milestone in the Company’s mission to provide innovative solutions for addictions, weight loss and mental health disorders. The first site to be initiated is IMCA in Israel and will be led by Prof. Mark Weiser, head of the Psychiatric Division at the Sheba Medical Center, whose specializations include cognitive impairment in persons with psychiatric disorders, such as substance abuse, depression and personality disorders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
- SciSparc announces publication of patent via Clearmind collaboration
- Clearmind announces patent publication for cocaine addiction treatment by KIPO
- Psychedelic: MindMed reports Q4 earnings results
- Psychedelic: GH Research, Compass Pathways report earnings results